Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals reported Q1 net product revenue of $60.1 million, highlighting a strong U.S. launch for IMCIVREE with over 150 patient start forms in the first six weeks. The European Commission granted Marketing Authorization for IMCIVREE in acquired hypothalamic obesity, though the Phase 3 EMANATE trial failed to achieve its primary endpoint in four independent substudies.
Key figures
- Revenue
- $60.1 million
- Drug Name
- IMCIVREE (setmelanotide)
- Guidance
- 2026 Non-GAAP Operating Expenses $385M-$415M
- Phase Of Trial
- Phase 3
- Net Loss
- $56.7 million
- Cash Position
- $340.6 million
- Patient Start Forms
- 150
- Us Revenue Sequential Change
- -5%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.